Onfekafusp alfa in addition to doxorubicin for advanced or metastatic soft tissue sarcoma – first line

featured image
Indications: Soft tissue sarcoma
Therapeutic Areas: Sarcoma
Year: 2019

Onfekafusp alfa in addition to doxorubicin is in clinical development for the treatment of advanced or metastatic soft tissue sarcoma. Soft tissue sarcomas are a group of rare cancers affecting the tissues that connect, support and surround other body structures and organs. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue sarcomas can develop in almost any part of the body, including the legs, arms and torso. Doxorubicin is used as a standard-of-care drug in sarcoma and is commonly administered in combination with other chemotherapy drugs. These combinations do not significantly increase survival rates and are associated with substantial toxicities.
Onfekafusp alfa consists of an anti-body that selectively targets tumour blood vessels, and an anti-tumour agent which exerts toxic effects on tumour-associated blood vessels and causes an increase of the antitumour immune response. Doxorubicin is a chemotherapy drug which slows or stops cancer cell growth. This treatment may address the need for improved therapies for people who cannot have surgery and currently have limited options.